Navigation Links
Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter
Date:9/3/2014

s in 2013 and they have a strong and growing presence in Europe and other regions," stated Carl Spana, Ph.D., President and CEO of Palatin.  "This collaboration is aligned with Palatin's global strategy to bring bremelanotide to the market for the millions of women who have female sexual dysfunction and are seeking a safe and effective treatment." Dr. Spana further stated that, "In addition, we are focused on starting the bremelanotide phase 3 clinical trials in the U.S. in the fourth quarter of 2014 and on furthering discussions for partnerships for the U.S. and other territories."

Erik Bogsch, Chief Executive Officer of Richter, commented, "We are pleased to partner with Palatin and assist in the advancement of the bremelanotide program for the treatment of female sexual dysfunction. Female Healthcare is an important area of our strategy and is growing nicely. We are committed to development activities to treat conditions in women that have a severe impact on the patient's quality of life. Bremelanotide complements our active strategy to bring innovative and first-in-class compounds to market and we look forward to advancing bremelanotide to address the large, unmet medical needs of women with female sexual dysfunction."

About Bremelanotide for Female Sexual Dysfunction

Palatin is developing bremelanotide subcutaneous for the treatment of FSD in premenopausal women diagnosed with FSD. Bremelanotide, which is a melanocortin agonist (a compound which binds to a cell receptor and triggers a response) drug candidate, is a synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone).

About Female Sexual Dysfunction

Female Sexual Dysfunction covers multi-factorial conditions that have anatomical, physiological, medical, psychological and social components. We will seek approval of bremelanotid
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Palatin Technologies Responds to Unusual Market Activity
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on November 14, 2013
3. Palatin Technologies Announces Option for License to Bremelanotide in Europe
4. Palatin Technologies Announces Issuance of Two Natriuretic Peptide Receptor-Specific Mimetic Patents
5. Palatin Technologies, Inc. To Report First Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on November 14, 2013
6. Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial
7. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2013 Results
8. Palatin Technologies, Inc. To Report Fiscal Year 2013 Fourth Quarter Results
9. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
10. Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
11. Global Markets and Technologies for Molecular Imaging Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015 STAAR Surgical Company (NASDAQ: ... lenses and delivery systems for the eye, today announced that ... to the Company,s Board. Mr. Wall ... Boston -based investment firm, for more than nine ... of Directors, and chair of the Corporate Governance Committee and ...
(Date:9/2/2015)... , Sept. 2, 2015   Physicians Rx ... Bernstein has joined the organization as President and ... recently served as President and Chief Executive Officer for ... Chief Executive Officer of Physicians Rx Pharmacy, be responsible ... "We are extremely pleased to bring Gaston on ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/l8z67c/pharmaceutical ) has announced ... (Basel, Switzerland - November 26-27, 2015)" conference to their ... overview of the key areas of pharmaceutical regulatory affairs in ... , Macau and Taiwan ... important aspects of gaining and maintaining a successful Marketing Authorisation ...
Breaking Medicine Technology:William P. Wall Appointed to STAAR Surgical Board of Directors 2Gaston L. Bernstein Named President and CEO of Physicians Rx Pharmacy 2Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2
... Tim Wentworth, group president for employer and key ... MHS ), is scheduled to present at the Lazard ... 17, 2010 in New York. (Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO) ... The St. Regis Hotel is scheduled to begin at ...
... Despite national guidelines recommending that inhaled corticosteroid (ICS) ... with mild persistent asthma, a new study finds that ... drugs that combine an ICS and a long-acting beta ... noted based on pharmacy and medical claims. The analysis ...
Cached Medicine Technology:Medco to Present at the Lazard Capital Markets 7th Annual Healthcare Conference 2New Study: Overuse of Combination Drug Therapy in Patients with Mild Asthma Leads to Increased Costs 2New Study: Overuse of Combination Drug Therapy in Patients with Mild Asthma Leads to Increased Costs 3New Study: Overuse of Combination Drug Therapy in Patients with Mild Asthma Leads to Increased Costs 4
(Date:9/2/2015)... ... September 02, 2015 , ... ... in the news recently following a decision by the Centers for Medicare & ... likely to average approximately $71,000 or roughly 40% of its headline-grabbing $178,000 price ...
(Date:9/2/2015)... ... 02, 2015 , ... Date and time: Oct. 3, 2015, 9 a.m. to ... Tomlinson Road, Bryn Athyn, Pa 19009 , Cost: $50 per person; includes lunch , ... Times best-selling author Sam Keen based on his new book which he co-authored with ...
(Date:9/2/2015)... CA (PRWEB) , ... September 02, 2015 , ... In ... featured by the Huffington Post on August 25th, writer Akela Stanfield detailed her lifelong ... While the author acknowledged that she had always seen herself as someone who would ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... endpoint data collection, cloud analytics and workflow solutions today announced the September ... pharmaceutical researchers to participate in interactive programs in which ERT scientists and ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... healthcare industry announced today the launch of its enhanced, cloud-based mobile ePrescribing application. ... look” and focus on improving prescriber usability. A leader in health technology, RxNT ...
Breaking Medicine News(10 mins):Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2Health News:Recent Editorial on Bariatric Surgery Acceptance Illuminates a Typical Journey Towards Weight Loss Surgery, Notes Dr. Michael Feiz 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 3Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2
... New analyses from the Women,s Health Initiative (WHI) confirm that ... healthy postmenopausal women. Researchers report a trend toward an ... of hormone therapy among women who began therapy within 10 ... among women who began hormone therapy more than 10 years ...
... disease activity when added to interferon beta , TUESDAY, ... to standard treatment with interferon beta may reduce multiple ... new study reports. , Previous non-randomized studies found that ... disease activity. , This new phase 2 study ...
... ... 2010 , ... February 16, 2010 -- Aberdeen Group, a Harte-Hanks Company has released a new benchmark ... Telecom Expense Management (TEM) solutions as a strategic foundation and precursor for other ...
... ... all natural food service company manages to grow sales and reduce its ... second year in a row, Service Foods, the largest Home Food service ... after increasing sales. Verus Carbon Neutral once again measured and offset 100% ...
... ... Texas, has contracted with Atlanta-based Premier Anesthesia to manage the anesthesia services for its ... ... hospital in east Texas, has contracted with Atlanta-based Premier Anesthesia to manage the anesthesia ...
... ABBOTT PARK, Ill., Feb. 16 Abbott (NYSE: ... EUR 4.5 billion ( $6.2 billion ) acquisition of ... portfolio of pharmaceutical products and expanding Abbott,s presence in key global ... Abbott expects the acquisition to add approximately $2.9 billion ...
Cached Medicine News:Health News:WHI data confirm short-term heart disease risks of combination menopausal hormone therapy 2Health News:WHI data confirm short-term heart disease risks of combination menopausal hormone therapy 3Health News:WHI data confirm short-term heart disease risks of combination menopausal hormone therapy 4Health News:Added Drug Aids MS Treatment 2Health News:AnchorPoint Sponsored Aberdeen Group Report Addresses Telecom Lifecycle Management 2Health News:AnchorPoint Sponsored Aberdeen Group Report Addresses Telecom Lifecycle Management 3Health News:AnchorPoint Sponsored Aberdeen Group Report Addresses Telecom Lifecycle Management 4Health News:AnchorPoint Sponsored Aberdeen Group Report Addresses Telecom Lifecycle Management 5Health News:Service Foods Reduces its Carbon Footprint and Grows Sales 2Health News:Service Foods Reduces its Carbon Footprint and Grows Sales 3Health News:Premier Anesthesia Forges New Partnership with Texas Hospital 2Health News:Abbott Completes Acquisition of Solvay Pharmaceuticals 2Health News:Abbott Completes Acquisition of Solvay Pharmaceuticals 3
Cer-Met series II system....
The Ceracup has a standard profile plastic component with a ceramic insert and the benefit of alumina-alumina contact....
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
Medicine Products: